In a recent trial of non-alcoholic fatty liver disease (NAFLD) (164), acetyl-coenzyme A carboxylase (ACC) inhibitor was used alone or cooperated with a diacylglycerol acyltransferase 2 (DGAT2) inhibitor in patients to observe the change of magnetic resonance imaging - proton density fat fraction in liver. Here, DGAT2 is linked to metabolic dysfunction-associated steatotic liver disease.